Paul Nghiem, MD, PhD, University of Washington, Seattle, WA, gives an overview of the early management of merkel cell carcinoma (MCC), higlighting the importance of a baseline PET scan. Prof. Ngheim reports that one in six patients with MCC will have an upstaging with a baseline PET scan. FInally, Prof. Ngheim discusses challenges around the integration of radiotherapy and surgery. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Paul Nghiem, MD, PhD, has served on an advisory board for EMD Serono and Pfizer and has received institutional research funding to institution from Bristol Myers Squibb and EMD Serono.